Evaxion A (EVAX) Shares Outstanding (2019 - 2026)
Evaxion A's (EVAX) quarterly Shares Outstanding (Entity) came in at $8.3 million in Q1 2026, up 150826.8% YoY from N/an in Q1 2025, and up 30.15% on a QoQ basis from $6.4 million in Q4 2025.
Evaxion A (EVAX) Shares Outstanding (2019 - 2026) Analysis & Trends
Evaxion A (EVAX) has 8 years of Shares Outstanding (Entity) data on file, last reported at $8.3 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 150826.8% year-over-year to $8.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.3 million (up 150826.8% YoY) and the FY2025 annual result came in at $6.4 million, up 119365.47% from the prior year.
- Shares Outstanding (Entity) grew to $8.3 million in Q1 2026, from $6.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $23.3 million in Q1 2024 to a low of $24.0 in Q4 2022.
- A 5-year average of $2.2 million and a median of $5364.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) soared 1808986.11% — and 2025, when it tumbled 99.98%.
- Tracing EVAX's Shares Outstanding (Entity) over 5 years: stood at $24.0 in 2022, then increased by 12.5% to $27.0 in 2023, then surged by 19766.67% to $5364.0 in 2024, then surged by 119365.47% to $6.4 million in 2025, then jumped by 30.15% to $8.3 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $8.3 million (Q1 2026), $6.4 million (Q4 2025), and $6361.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - | 8.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 417.01 Mn |
| Dec 31, 2025 | 320.41 Mn |
| Sep 30, 2025 | 318.04 Mn |
| Jun 30, 2025 | 315.83 Mn |
| Mar 31, 2025 | 276.31 Mn |
| Dec 31, 2024 | 53.64 Mn |
| Sep 30, 2024 | 276.28 Mn |
| Jun 30, 2024 | 53.79 Mn |
| Mar 31, 2024 | 233.19 Mn |
| Dec 31, 2023 | 27.34 Mn |
| Sep 30, 2023 | 1.38 Bn |
| Jun 30, 2023 | 132.19 Mn |
| Mar 31, 2023 | 1.29 Bn |
| Dec 31, 2022 | 23.64 Mn |
| Sep 30, 2022 | 1.19 Bn |
| Jun 30, 2022 | 1.17 Bn |
| Mar 31, 2022 | 1.16 Bn |
| Dec 31, 2021 | 974.66 Mn |
| Sep 30, 2021 | 959.93 Mn |
| Jun 30, 2021 | 959.93 Mn |